June 19 (NBD) -- Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced last Saturday that the application for clinical trial of the new anti-tumor injection, which is co-developed by its wholly-owned subsidiary and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., has been approved by the China Food and Drug Administration.

The injection is a novel recombinant anti-CD30 chimeric monoclonal antibody-MCC-DM1 conjugate that can be used to treat anaplastic large-cell lymphoma, Hodgkin lymphoma and cutaneous T cell lymphoma.

So far, about 36 million yuan (5.6 million U.S. dollars) has been put into the R&D of the new drug.

In the global market, similar targeted drug Adcetris developed by the U.S.-based Seattle Genetics generated sales totaling 640 million U.S. dollars last year.

But there is no alternatives available in the domestic market, according to the company's announcement.

Email: tanyuhan@nbd.com.cn